Background
==========

High-risk HPV type infections is detected with polymerase chain reaction (PCR) in approximately 15% of esophageal carcinoma patients \[[@B1]\]. The incidence of high-risk HPV type in esophageal carcinoma varies between different geographical areas \[[@B1]\]. It is postulated that areas with high incidence of esophageal carcinoma have higher rates of HPV than in areas with low incidence of esophageal carcinoma \[[@B2]\]. According to epidemiological studies, HPV 16 is the most prevalent HPV type in cervical cancer, followed by HPV 18, 45, 31, and 33, in descending order \[[@B3]\]. HPV infections of squamous cells can induce hyperplasia and papilloma \[[@B4]\] and *in vitro*studies have further revealed that the exposing of human fetal esophageal cells to HPV-18 results in immortalization and development of human esophageal carcinoma cells \[[@B5]\].

In patients with tonsil cancer, the presence of HPV in the tumors correlates with better survival \[[@B6]\]. In a study of patients with cervical carcinoma receiving radiation therapy, HPV-positive patients have a significantly better survival rate \[[@B7]\]. However, within *in vitro*studies the chemosensitivity as well as radiation sensitivity is decreased in HPV-infected cells \[[@B8],[@B9]\]. The immune response might affect survival, but this seems to depend on the whether HPV is present in episomal form or as integrated virus. In patients with cervical carcinomas, higher quantities of antibodies against HPV-16 is seen with episomal HPV as compared to integrated HPV DNA \[[@B10]\]. The mechanisms used by high-risk HPV genotypes (HPV 16, 18, 31, 33, 39, 45, 52, 58 and 67) to overcome the normal cell cycle control is mediated by the HPV viral oncoproteins E6 and E7, which cause inactivation of the tumor suppressor genes p53 and Rb \[[@B11]\].

In the present study, viral load in a series of high-risk HPV types (16, 18, 31, 33, 39, 45, 52, 58 and 67) were determined in esophageal carcinoma tumors. Secondary, as a pilot study we investigated the association between HPV status and survival in patients with esophageal carcinoma.

Methods
=======

Ethics
------

The study was reviewed and approved by the research ethics committee, Uppsala University, Uppsala, Sweden.

Patients characteristics
------------------------

Patients with esophageal carcinoma, admitted to the Department of Oncology, University Hospital, Uppsala, Sweden, during 1990--2000 were identified. These patients formed a consecutive series. A total of 126 patients fulfilled the inclusion criteria but 26 patients were lost due to inadequate (n = 9) or absence of histological material (n = 17). The present study is based on a retrospective examination of esophageal carcinoma diagnostic biopsy samples from clinical cases, all retrieved tumor samples were re-evaluated before analysis.

The following parameters were studied: age, gender, weight loss, performance status according to the Eastern Cooperative Oncology Group (ECOG) \[[@B12]\] at first admittance, smoking habits, alcohol habits and differentiation of the tumor. Anatomical localization of the tumor were grouped into an upper part (15--24 cm), a middle part (25--34 cm) and a lower part of the esophagus (35--46 cm. The tumor status were characterized into localized (Primary tumor with or without local node metastases) or advanced disease (With distant metastases).

Treatment strategy was recorded as:

1\. Preoperative radiation treatment, total dose of 40 Gy in 2 Gy fractions. This irradiation was given concomitant with chemotherapy (Cisplatin 100 mg/m^2^and 5-FU 750 mg/m^2^, three cycles with an interval of three weeks of which two were given concomitantly).

2\. Curatively intended radiation treatment, total doses 60--64 Gy.

3\. Palliative treatment included radiation treatment, total dose 36 Gy in 3 Gy fractions. These patients also received brachytherapy and in some cases, also palliative chemotherapy.

4\. Palliative treatment only including chemotherapy.

HPV plasmids
------------

Plasmids containing HPV 16, 18, 31, 33, 39, 45, 52, 58 and 67 were supplied by T. Matsukura (National Institute of Health, Japan), A. Lörincz (Digene Corporation) or G. Orth (Institut Pasteur, Paris) or prepared by cloning from PCR products of clinical samples. The plasmids were used both as positive controls and to estimate the sensitivity of the assay.

Deparaffination procedure
-------------------------

The biopsies were fixated by treatment in buffered formalin followed by paraffin embedding. Paraffin blocks from the primary tumor were cut in 10-μm sections and 4 sections/patient were collected in the same microcentrifuge tube. Samples were de-waxed in 1 ml xylene for 5 min. in room temperature and centrifuged at 14,000 rpm for 5 min. The supernatant was removed. This step was then repeated 5 times. Samples were gently vortexed between each step. 1 ml 95% ethanol was then added for 5 min. in room temperature and this was repeated with 70% ethanol. The samples were centrifuged 14.000 rpm for 5 min. between the ethanol changes. The samples were then dried in a 37°C heated block with open lids for 20 min. to remove residual ethanol.

Proteinase K digestion
----------------------

200--400 μl of dilution buffer was added to each tube (0.2 M Tris-HCL pH 8.0, 1% sodium dodecyl sulfate, 10 mM EDTA, 1 mg/ml proteinase K). The volume of the dilution buffer was dependent of the amount of tissue available. Samples were subsequently incubated at 50°C overnight and thereafter heated to 94°C for 10 min. to inactivate the proteinase K.

Protein precipitation
---------------------

50 μl of saturated NaCl solution (approximately 6 M) was added to each tube and the samples gently vortexed for 5 min. The tubes were then centrifuged at 14.000 rpm at room temperature for 5 min. After centrifugation, white pellets were visible in the bottom of the tubes and supernatants were transferred to a new tube.

DNA precipitation
-----------------

DNA was precipitated with 2.5 volumes of 95% ethanol in -20°C for 1 hour and then pelleted by centrifugation at 14.000 rpm in room temperature for 30 min. The pellet was then washed with 70% ethanol followed by centrifugation for 5 min. DNA pellets were air dried and finally re-suspended in 100 μl TE buffer (100 mM Tris-HCL, pH8.0, 1 mM EDTA).

Real-time PCR
-------------

The detection of the HPV was performed using a real-time PCR based method previously described \[[@B13]\]. Briefly, the real-time PCR assay detects and quantifies HPV 16, 18, 31, 33, 39, 45, 52, 58 and 67. The assay is based on three parallel real-time PCRs from each patient sample: a) Reaction 1 detects and quantifies HPV types 16, 31, 18 and 45 (HPV 18 and 45 detected and quantified together) using three different fluorophores, b) Reaction 2 detects and quantifies HPV types 33, 39, 52, 58 and 67 (HPV 33, 52, 58 and 67 detected and quantified together), again using three different fluorophores, and c) Reaction 3 detects and quantifies the amount of a human single copy gene (HMBS, Homo sapiens hydroxymethylbilane synthase, GenBank accession number M95623.1). Reaction 1 includes a total of seven PCR primers and three probes, Reaction 2 a total of five PCR primers and two probes and Reaction 3, two PCR primers and a single probe. All probe and primer sequences have been described \[[@B13]\]. By relating the HPV copy number to the number of nuclear gene equivalents (from Reaction 3) a measure of HPV load is obtained.

The system has a dynamic range from 10^2^to 10^7^HPV copies per assay and is applicable to both fresh clinical samples and DNA extracted from archival samples. Reconstitution experiments, made to mimic infections with several HPV types, shows that individual HPV types can be detected in a mixture as long as they represent 1--10 percent of the main type. The system has been evaluated with respect to technical specificity and sensitivity, reproducibility, reagents stability, sample preparation protocol and applied to the analysis of clinical samples. This homogeneous assay provides a fast and sensitive way for estimating the viral load of a series of the most frequent oncogenic HPV types in biopsies.

The PCR amplification was performed in a 25 μl volume containing 1× PCR buffer gold (Applied Biosystems, Foster City, CA, USA), 300 μM 6-carboxy-X-rodamine (Molecular Probes inc, Eugene OR, USA), 3.5 mM MgCl~2~, 200 nM each of dATP, dCTP, dGTP and 400 nM dUTP (Pharmacia Biotech, Uppsala, Sweden), 0.625 U AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA), 3 μg BSA (Sigma Chemical Co., St. Louis, MO, USA) and 200 nM of each primer and probe, and 3 μl DNA extract. Amplification and detection was performed using a 7700 Sequence Detection System (Applied Biosystems Inc., Foster City, CA, USA). The amplification ramp included an initial hold step of 10 min. at 95°C followed by a two-step cycle consisting of 15 sec. at 95°C and 1 min. at 57°C, repeated 40 times. Each real-time PCR run included reactions with no template controls containing all PCR components but without template DNA to ensure that the reagents mix were free of contaminants.

Statistics
----------

The survival rates were estimated with the Kaplan-Meier product limit method, whereas univariate analysis was performed with log-rank test. Cox regression analysis was performed to investigate if certain continuous factors had a significant effect on survival. Spearman\'s rank order correlation was utilized for tests of associations between factors. A 5% significance level was used throughout the study.

Results
=======

A total of 100 patients with esophageal carcinoma were investigated for the presence of the following types of human papilloma virus 16, 18, 31, 33, 39, 45, 52, 58, and 67. The patients were followed until 2003 with a median follow up time of 297 days (5--3675 days) and 11 (11%) patients were alive after follow-up. Patient\'s characteristic, median survival and median viral load for each investigated parameter are listed in Table [1](#T1){ref-type="table"}. Univariate analysis revealed that tumor stage (p = 0.00071) and performance status according to ECOG (p \< 0.0001) were associated with survival. HPV positive patients characteristics are listed in Table [2](#T2){ref-type="table"} including viral load, gender, performance status, stage of disease (localized or with metastases), treatment approach and survival time.

Prior to the analysis of clinical samples, standard curves for the different HPV types were generated based on dilution series of the HPV plasmids, as described \[[@B13]\]. Each run of samples included negative controls (no PCR template) and positive controls (HPV plasmid in low copy number). In none of the real-time runs did the controls yield a different signal than that expected. Reaction 3 (containing the reagents for the nuclear single copy gene HMBS) was used to evaluate the DNA quality. Only samples with positive reaction was further investigated for HPV type. The HMBS assay was positive, i.e. the reactions contained DNA suitable for PCR, in all tumors examined. Amplification of HPV 16 DNA was detected in 16% of the patients and no other HPV type was detected. HPV 16 status did not influence survival rate (p = 0.72) (Figure [1](#F1){ref-type="fig"}). The HPV 16 viral load varied between samples with a median HPV 16 viral load of 4.3 genomes/human genome equivalents, but no correlation with survival rate was detected (p = 0.44) (Figure [2](#F2){ref-type="fig"}). Histological subgroups did not have a difference in survival depending on HPV 16 status, either in patients with squamous cell carcinoma (p = 0.61) or adenocarcinoma (p = 0.49). Finally, HPV 16 status did not have any effect on survival after radiation treatment (p = 0.16) or chemotherapy (p = 0.22).

Discussion
==========

HPV is an important risk factor for development of cervical cancer as well as head/neck and anal cancer \[[@B14]-[@B17]\]. In the present study we investigated the presence and viral load of a series of high-risk HPV genotypes in 100 patients with esophageal carcinoma using real-time PCR. Tonsil cancer as well as tumors located in the oropharynx and hypopharynx have high rates of HPV positive cases. In tonsil and oropharyngeal tumors approximately half of all cases harbor detectable HPV, whereas in tumors in the oral cavity and hypopharynx HPV is detected in approximately 20% of all cases. According to earlier studies, HPV 16 is the most common type of HPV associated with head and neck malignancies, while other high-risk HPV types are rare \[[@B13],[@B14]\]. Smoking and excessive alcohol consumption is considered risk factors for both squamous cell carcinomas and tonsil cancer. However, a subgroup of younger, no smoking tonsil cancer patients with HPV positive tumors indicates a different etiology for tonsil cancer besides excess smoking and alcohol consumption \[[@B6],[@B13]\]. In the present study, we were unable to address this because of few observations in the HPV positive group of patients.

Viral load has previously been investigated in esophageal carcinoma tumors with PCR technology \[[@B18]\]. Si et al report up to 157 genomes/human genome equivalents for HPV 16 in esophageal carcinoma tumors. By contrast, HPV 18 was only detected in 6 of 319 cases and a median HPV viral load of 4.9 genomes/human genome equivalents \[[@B18]\]. Weston et al differentiates the HPV types as high risk and low risk HPV types and report one of 40 cases with a high risk HPV type \[[@B19]\]. In our study, HPV 16 was detected in 16% of the cases, but none of the other viral types were found.

The prognostic value of HPV status has previously been investigated in patients with esophageal carcinoma \[[@B20],[@B21]\]. Furihata et al report that HPV positive patients have worse survival than HPV negative patients with an over-expression of p53 in esophageal carcinoma patients. They conclude that each of the two factors, HPV infection and p53 over-expression, indicate poor prognosis \[[@B21]\]. Hippelainen et al examined 61 patients with esophageal carcinomas and report that HPV were involved in 11% of the tumors but without prognostic value for presence of HPV \[[@B20]\]. In the present study, HPV 16 infection was not associated with higher survival rate. However, for patients having a HPV 16 viral load \> 1.0 viral genome per cell, an indication of higher survival rate was found in comparison with patients having a HPV 16 viral load \< 1.0 viral genome per cell (Figure [2](#F2){ref-type="fig"}).

Lindel et al report HPV status as a prognostic parameter for radiotherapy response in cervical carcinoma patients \[[@B22]\]. Further, Harima et al report that HPV negative patients have poorer outcome than HPV positive patients after radiotherapy and concludes that HPV status might be useful to optimize for treatment options \[[@B7]\].

We investigated the HPV positive patients in relation to treatment. HPV positive patients receiving radiation treatment indicated a trend towards better survival, although this was not statistically significant (p = 0.16). Integration of HPV result in higher expression of the oncoproteins E6/E7, thereby abrogating the p53 and Rb protein functions, promoting genomic rearrangements \[[@B23]\] and development of cervical carcinoma \[[@B24]\]. Rearranged DNA is theoretically more sensitive to radiation, providing an explanation for the indication of a higher survival rate for patients with HPV positive tumors. However, our results should be interpreted with caution due to the small number of cases investigated. For patients receiving chemotherapeutic treatment (mainly neoadjuvant cisplatin-based chemotherapeutic combinations), we see a tendency towards better survival (p = 0.22). *In vitro*studies report that cisplatin sensitivity is increased in HPV 16 transfected ovarian cancer cells \[[@B25]\], in accordance with results from the present study.

In conclusion, we employed a sensitive real-time PCR assay for analysis of paraffin-embedded tissue from patients with esophageal carcinoma. Among the 100 patients investigated, HPV 16 was present in 16% of the patients. Given the limited sample size, the results of this pilot study should be interpreted with caution. However, the results indicate a positive association of HPV 16 viral load with survival and motivate further studies of the role of HPV 16 viral load in patients with esophageal carcinoma.

Conclusion
==========

Only HPV 16 was detected among the patients. HPV 16 in esophageal carcinoma patients did not influence survival or improve therapy response. However, given the size of the study there is a need to examine a larger cohort in order to understand in more detail the effect of high risk HPV types in esophageal carcinoma.
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###### 

Demographic description of patients for all investigated parameters. The distribution of HPV 16 positivity and median viral load is shown for all clinical subgroups. Tumor stage and performance status according to ECOG were correlated to patients survival in the univariate survival analysis, p-value is shown for all parameters. \*Treatment management not included in survival analysis.

                                             Number of patients   Median survival in days   Univariate survival analysis p-value for each parameter   HPV 16 pos   HPV 16 viral load median value based on positive samples (genomes/human genome equivalents)
  ------------------------------------------ -------------------- ------------------------- --------------------------------------------------------- ------------ ---------------------------------------------------------------------------------------------
  **Gender**                                                                                0.55                                                                   
  Male                                       71                   292                                                                                 10           2.7
  Female                                     29                   338                                                                                 6            10.5
  **Age**                                                                                   0.84                                                                   
  65                                         39                   292                                                                                 7            2.1
  65 +                                       61                   307                                                                                 9            6.6
  **Tumour stage**                                                                          0.00055                                                                
  Advanced disease                           30                   212                                                                                 5            2.12
  Localised disease                          70                   376                                                                                 11           5.3
  **Histology**                                                                             0.39                                                                   
  Squamous cell carcinoma                    71                   250                                                                                 10           16.4
  Adenocarcinoma                             27                   374                                                                                 5            0.6
  Mucoepidermoid                             2                    528                                                                                 1            5.3
  **Tumor differentiation**                                                                 0.46                                                                   
  Low differentiated                         29                   362                                                                                 4            1.4
  Middle                                     23                   234                                                                                 4            1.9
  High                                       2                    187                                                                                 0            \-
  Not determined                             46                                                                                                                    
  **Localisation of tumor**                                                                 0.17                                                                   
  Upper                                      11                   292                                                                                 3            15.7
  Middle                                     33                   338                                                                                 6            16.9
  Lower                                      47                   235                                                                                 3            0.16
  Not determined                             9                                                                                                                     
  **Performance status**                                                                    \<0.0001                                                               
  0                                          43                   419                                                                                 6            2.7
  1                                          43                   235                                                                                 4            16.3
  2                                          8                    120                                                                                 2            60.6
  3                                          4                    49                                                                                  3            0.6
  Not determined                             2                                                                                                                     
  **Weight**                                                                                0.12                                                                   
  Weight loss                                82                   236                                                                                 10           0.6
  No weight loss                             18                   414                                                                                 6            6.0
  **Smoking habits**                                                                        0.45                                                                   
  Non smoker                                 16                   309                                                                                 1            5.3
  Smoker                                     45                   292                                                                                 4            8.7
  Ex-smokers                                 22                   235                                                                                 6            2.7
  Not determined                             17                                                                                                                    
  **Alcohol usage**                                                                         0.81                                                                   
  Alcohol use                                50                   339                                                                                 6            5
  No alcoholic use                           6                    450                                                                                 1            5
  Not determined                             44                                                                                                                    
  *Treatment*                                                                               \*                                                                     
  Surgery+ Chemo-radiation                   13                   493                                                                                 1            0.5
  Curativ intended Chemo-radiation           24                   445                                                                                 5            5,3
  Palliative chemotherapy and radiotherapy   47                   234                                                                                 5            15,7
  Palliative chemotherapy                    16                   125                                                                                 5            0.6

###### 

Description of HPV positive patients characteristics including viral load, gender, histology, performance status, stage of disease, survival days and treatment strategy. \*genomes/human genome equivalents. \*\*alive at follow up, censored in the survival analyze. Nd-the parameter could not be determined. Histology: ESCC-Squamous cell carcinoma, AC-Adenocarcinoma, MEC-Mucoepidermoid carcinoma. Treatment strategy: 1. Pre-operative concommitant chemoradiotherapy, 2. Curatively intended radiotherapy 2--60 Gy, 3. Palliative intended radiotherapy and chemotherapy, 4. Palliative care including chemotherapy.

  **HPV16 Viral load\***   **Gender**   **Histology**   **Performace status**   **Advanced disease**   **Survival days**   **Treatment strategy**
  ------------------------ ------------ --------------- ----------------------- ---------------------- ------------------- ------------------------
  437,0                    Male         ESCC            3                       No                     23                  3
  \< 94                    Women        ESCC            2                       Yes                    207                 2
  \<31                     Male         ESCC            1                       No                     98                  3
  27,3                     Male         ESCC            2                       Yes                    30                  4
  \<17                     Women        ESCC            1                       No                     1569                2
  15,7                     Women        ESCC            1                       No                     626                 3
  6,6                      Male         ESCC            0                       No                     \*\*1343            3
  5,3                      Women        MEC             0                       No                     650                 2
                                                                                                                           
  3,3                      Male         ESCC            0                       No                     1028                2
  2,1                      Male         AC              0                       Yes                    1870                4
  0,6                      Male         AC              nd                      No                     1854                3
  0,6                      Women        AC              3                       No                     73                  4
  0,5                      Male         ESCC            0                       No                     492                 1
  0,2                      Male         AC              0                       No                     934                 2
  0,2                      Women        AC              1                       Yes                    168                 4
  0,1                      Male         ESCC            3                       Yes                    6                   4
